An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.

An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite. Abstract Text:

C Erlichman,

N-Phosphonacetyl-L-aspartic acid (PALA) is new synthetic antimetabolite which inhibits de novo pyrimidine biosynthesis. Its significant activity against Lewis lung carcinoma, B16 melanoma, and glioma 26 suggested that it might be useful in the treatment of human solid tumors. Phase I trials revealed that dose-limiting toxicity included skin reactions, diarrhea, and stomatitis. Pharmacologic studies demonstrated rapid renal excretion of more than 70% of the unmetabolized drug in 24 h. Peak plasma levels correlated with dose of PALA administered. Partial responses to PALA were seen in one patient with melanoma, one with chondrosarcoma, and one with colon carcinoma. The potential for PALA's use in combination chemotherapy, particularly with 5-fluorouracil, is discussed.

An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite. Publishing Authors By Initials

C Erlichman,

For similar organic chemicals: carboxylic acids: acids, acyclic: acetic acids: phosphonoacetic acid research abstracts see: organic chemicals: carboxylic acids: acids, acyclic: acetic acids: phosphonoacetic acid research

PUBMED ID PMID:

MEDLINE DATE:

An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Recent results in cancer research. Fortschritte de

VOLUME: 74

Page Numbers: 65-71

Journal Abbreviation: Recent Results Cancer Res.

ISSN: 0080-0015

DAY: 13

MONTH: 02

YEAR: 1980

An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 44671

An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite. Keywords Mesh Terms:

KEYWORDS: Phosphonoacetic Acid

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite. Information

Substance Name: Aspartic Acid

Registry Number: 56-84-8

Grant and Affiliation Information for An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.

AFFILIATION:

Country: GERMANY, WEST

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Recent Results Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate PALA, a new antimetabolite Related Publications

• A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
• An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
• Cisplatin abrogates the geldanamycin-induced heat shock response.
• Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001.
• HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
• P-glycoprotein-mediated resistance to hsp90-directed therapy is eclipsed by the heat shock response.
• Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
• Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.